The last few weeks have seen a surge of interest in British biotech firms, say Telegraph business news writers.
Among those benefiting in the UK are Cambridge Antibody Technology, which makes antibodies for research and therapeutic use. Oxford Biomedica, which is developing genetic therapy treatments for cancer, has also seen share prices soar. 'There has been a wake-up call to the real value of some of these new technologies and companies', says analyst Nick Woolf.
The revival follows a similar change in fortune for the US biotech industry. Much of the recent investment there is thought to have come from those who made huge profits from IT stocks, and are now looking for new growth opportunities.
Sources and References
-
Britain's biotech boffins bounce back
-
Oxford's spires can dream on
Leave a Reply
You must be logged in to post a comment.